Actinogen Medical Limited (ASX:ACW) Managing Director and CEO, Dr Bill Ketelbey presents an update on the company's lead Alzheimer Phase II drug candidate XanADu and its expanded clinical development program for Xanamem at FNN's Investor Event.
- Xanamem lead compound for the treatment of Alzheimer's disease
- Also considered for other cortisol-associated cognitive impairment
- Reducing brain cortisol production
- Experienced board and management
- Expert clinical and scientific advisory boards
- Phase II trial currently underway
- Substantial institutional investment
- A huge market with significant unmet need
For more, watch the Managing Director and CEO, Dr Bill Ketelbey present.